Serum intact parathyroid hormone levels may be an early marker to predict postthyroidectomy hypocalcemia.
TransCon PTH is a long-acting prodrug of parathyroid hormone designed to restore PTH to physiologic levels, normalizing blood and urinary calcium levels, serum phosphate levels and bone turnover.
Investigators examined whether short-term treatment with an angiotensin II receptor blocker and/or vitamin D3 reduced PTH levels.
Vitamin D levels in preterm infants are significantly correlated with optimal calcium homeostasis and bone mineralization of the femur.
Shear wave elastography can be a useful tool in the preliminary diagnostics of parathyroid adenomas.
While parathyroid hormone levels may be used to anticipate calcium decline, a "normal" PTH level does not always correctly predict postoperative calcium level.
After parathyroidectomy, morbidity and mortality rates were considerably higher in patients with secondary and tertiary vs primary hyperparathyroidism.
Etelcalcetide shows promise for reducing parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
Lorraine Fitzpatrick, MD, discusses updated results from the ACTIVE phase 3 clinical trial.
Nancy E. Lane, MD, professor of medicine, at the University of California at Davis School of Medicine, discusses results from the phase 3 ACTIVE trial.
Study reveals 6-fold higher risk of secondary hyperparathyroidism in patients on furosemide vs hydrochlorothiazide.
The therapy was also associated with reduced urinary calcium excretion and stable serum calcium concentration in patients with hypoparathyroidism.
Reduced fracture risk for surgery; bisphosphonate treatment no better than observation
Recent data showed that parathyroidectomy is more effective for controlling hypercalcemia after kidney transplants in patients with persistent hyperparathyroidism.
The correlation persists regardless of concurrent oral bisphosphonate administration.
PTH (1-84) for 7 years is linked to reduced calcium and calcitriol supplementation.
Hemodialysis patients who undergo the procedure experience decreased risks of all-cause and cardiovascular mortality.
Cyclic treatment with teriparatide yields improvements in bone mineral density that are similar to daily treatment in women taking alendronate.
Shire announced the launch of Natpara (parathyroid hormone) for injection indicated as adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism
In patients with heart failure, the ratio of calcitriol to parathyroid hormone may help predict cardiovascular death.
Abaloparatide-SC, an injectable drug being studied for osteoporosis, may reduce the rate of new spinal fractures by 86%.
The FDA has approved Natpara (parathyroid hormone) to control hypocalcemia in patients with hypoparathyroidism.
Higher aldosterone levels are linked to increased parathyroid hormone levels, RAAS inhibitors are associated with lower parathyroid hormone concentrations.
Men with severe or complete vs. mild erectile dysfunction had significantly lower vitamin D levels.
Richard Quinton, MD, offers his take on these study findings and what they may mean for clinical practice.
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted to recommend approval of recombinant human parathyroid hormone for hypoparathyroidism.
Elevated parathyroid hormone levels may play a role in the development of vascular dementia.
More patients with abnormal bone mineral density should undergo screening for primary hyperparathyroidism.
Patients with hypoparathyroidism may benefit from treatment with recombinant human parathyroid hormone.
AMG 416 demonstrated positive results for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Fatigue Management Contributes to Effective Endometriosis Care
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Trulicity Labeling Updated to Include Data on T2D Patients With CKD
- New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D
- Peer-Led Education Helps Physicians Save Time With EHRs
- As Immigration Policies Tighten, Physician Shortage Concerns Grow